Selecta Biosciences (NASDAQ:SELB) Rating Increased to Buy at

analysts have also recently issued reports on the company. upgraded Selecta Biosciences from a 'hold' rating to a 'buy' rating.

In a report published on Thursday, the rating went from 'hold' to 'buy.

SELB has also been the subject of research by other analysts. Needham & Company LLC reiterated a buy' rating on Selecta Biosciences and set a price target of $5.00 in a report published on Thursday, April 13. TheStreet downgraded Selecta Biosciences's rating from a "c-" to a "d-" in a report published on Tuesday, May 16. HC Wainwright raised their price target on Selecta Biosciences to $5.00 in a report published on March 22nd. In a report published on March 22nd, Mizuho reduced their price target for Selecta Biosciences to $4.00 from $5.00. They also set a "buy" rating for the firm. Trading on Thursday saw a $0.07 gain, bringing the price to $1.25. The stock was traded at a volume of 2,039 775 shares, as opposed to the average of 1,175,321. The company has a simple moving-average of $1.19 for the last 50 days and $1.37 for the 200 day moving-average. The company has a $191.79-million market cap, a P/E ratio of -13.89, and a beta value of 1.17. Selecta Biosciences's 1 year low is $0.81, and its 1 year high is $2.73. The company's debt-to equity ratio is 0.22. It has a quick ratio (5.22) and a current rate of 522.

The company last announced its quarterly results on Thursday 4th May. The company's ($0.11) earnings-per-share (EPS) were below the consensus estimate of ($0.08) for the quarter by ($0.03). Revenue for the quarter was $5.94m, which is lower than analysts' expectations of $14.60m. Selecta Biosciences' negative net margin was 18.21%, and its negative return on equity was 17.67%. Analysts expect Selecta Biosciences to post a -0.39 earnings per share for the current fiscal year.

Selecta Biosciences: Institutional investors weigh in

Recently, hedge funds and institutional investors changed their stock holdings. Cubist Systematic Strategies LLC acquired a new stake of $25,000 in Selecta Biosciences at the beginning of the first quarter. Price T Rowe Associates Inc. MD increased its stake in Selecta Biosciences in the second quarter by 25,7%. Price T Rowe Associates Inc. MD owns 21,810 of the company stock, valued at $29,000. This is after purchasing an additional 4,464 during the last quarter. Virtu Financial LLC bought a new stake in Selecta Biosciences during the third quarter, valued at approximately $38,000. ExodusPoint Capital Management LP bought a new Selecta Biosciences position in the first quarter valued at approximately $33,000. Eqis Capital Management Inc. also purchased a position in Selecta Biosciences during the first quarter, valued at approximately $30,000. Institutional investors and hedge fund currently own 40.25%.

Selecta Biosciences Company profile

Get Rating

Selecta Biosciences, Inc. is a biopharmaceutical clinical-stage company that engages in research and development nanoparticle immunomodulatory drug for the treatment and preventive of human diseases. Portfolio includes pipelines, autoimmune therapy, gene therapy and biologic therapy. Omid C. founded the company. offers a FREE daily email newsletter